Triple-Negative Breast Cancer

Overview: What Is Triple-Negative Breast Cancer?

Triple-negative breast cancer (TNBC) is a less common but aggressive type of breast cancer. It gets its name because the cancer cells test negative for three common markers:

• Estrogen receptors (ER)
• Progesterone receptors (PR)
• Human epidermal growth factor receptor 2 (HER2)

Most breast cancers grow by using one or more of these markers, which allows doctors to target them with specific treatments like hormone therapy or HER2-targeted drugs. In triple-negative breast cancer, these markers are absent. This makes the cancer harder to treat, since it doesn’t respond to those targeted therapies.

Triple-negative breast cancer accounts for about 10–15% of all breast cancers. It is more likely to grow quickly, spread earlier, and come back after treatment compared to other breast cancers. Early detection plays a crucial role in improving survival, because treatment works best when the cancer is caught before it spreads.

What Are the Types of Triple-Negative Breast Cancer?

Triple-negative breast cancer is not one single disease. Researchers have identified several subtypes based on molecular and genetic differences:

• Basal-like TNBC: This is the most common subtype, resembling cells that line the breast ducts. Often aggressive but can respond well to chemotherapy.
• Immunomodulatory TNBC: This type is characterized by immune system activity in the tumor, which may respond to immunotherapy.
• Mesenchymal TNBC: This type is linked with cells that help the tumor grow and spread, sometimes resistant to chemotherapy.
• Luminal androgen receptor (LAR) TNBC: This type is driven by androgen (male hormone) pathways, which may open the door to hormonal or targeted treatments in the future.

Understanding the subtype helps doctors personalize treatment and improve outcomes.

What Are the Causes of Triple-Negative Breast Cancer?

The exact cause of triple-negative breast cancer is not fully understood, but cancer develops when normal breast cells mutate and begin to grow uncontrollably. Possible contributing factors include:

• Genetic mutations like BRCA1 and BRCA2, which are strongly linked to triple-negative breast cancer.
• Changes in DNA repair genes that allow cells to accumulate damage.
• Environmental triggers such as radiation or toxins.
• Hormonal risk factors (such as early menarche or late menopause) may contribute to risk, but the tumors themselves do not depend on estrogen or progesterone for growth.

In many cases, no single cause is found. Instead, it’s often a combination of genetics, lifestyle, and environment.

What Are the Risk Factors for Triple-Negative Breast Cancer?

Certain factors increase the likelihood of developing triple-negative breast cancer:

• Genetic risk: Women with BRCA1 mutations are at particularly high risk.
• Age: Triple-negative breast cancer is more common in women under 50.
• Race and ethnicity: Higher rates are seen in African American and Hispanic women.
• Family history: Having close relatives with breast cancer increases risk.
• Lifestyle factors: Obesity, lack of physical activity, alcohol use, and smoking may contribute.
• Reproductive factors: Early menstruation, late menopause, or never having children may slightly raise the risk.

What Are the Symptoms of Triple-Negative Breast Cancer?

Triple-negative breast cancer often doesn’t cause symptoms in the early stages, which is why screening is important. When symptoms do appear, they may include:

• A new lump in the breast or armpit.
• Breast pain or tenderness.
• Skin changes such as dimpling, redness, or thickening.
• Unexplained swelling in the breast.
• Nipple changes, such as inversion or discharge (not breast milk).

In advanced stages, symptoms may include bone pain, breathing difficulties, or unexplained weight loss if the cancer spreads.

How Is Triple-Negative Breast Cancer Diagnosed?

Doctors use several steps to detect and confirm triple-negative breast cancer:

• Clinical breast exam: A doctor checks for lumps or changes in the breast.
• Mammogram: X-ray images of the breast can detect suspicious growths.
• Breast Ultrasound: Helps distinguish between solid masses and fluid-filled cysts.
• Breast MRI: Provides detailed imaging, often used for high-risk patients.
• Biopsy: A small sample of tissue is taken and tested in the lab to confirm cancer. The biopsy also helps doctors determine the cancer’s grade and whether it has hormone receptors (estrogen and progesterone) or HER2 protein, which guide treatment decisions.

Staging of Triple-Negative Breast Cancer

Staging describes how far the cancer has spread, from Stage 0 (non-invasive) to Stage IV (spread to distant organs).

• Stage I: Small tumor, no spread.
• Stage II: Larger tumor or spread to nearby lymph nodes.
• Stage III: Cancer has spread to multiple lymph nodes or tissues near the breast.
• Stage IV: Cancer has spread to distant organs (metastatic breast cancer).

Grading describes how abnormal the cancer cells look under a microscope. A low grade means slow-growing, while a high-grade means more aggressive. TNBC is often high-grade, meaning cells look very different from normal and grow faster. Both staging and grading help doctors design the best treatment plan.

What Are the Treatment Options for Triple-Negative Breast Cancer?

Because triple-negative breast cancer lacks hormone and HER2 receptors, treatment relies on other approaches.

Surgery

• Lumpectomy: Removal of only the tumor and some surrounding tissue, preserving most of the breast.
• Mastectomy: Removal of the entire breast. Types of mastectomies include simple mastectomy, modified radical mastectomy, skin- and nipple-sparing mastectomy, endoscopy-assisted mastectomy, and prophylactic mastectomy.
• Oncoplastic surgery: Combines breast cancer surgery with cosmetic techniques to maintain breast shape.
• Sentinel lymph node biopsy: Checks whether cancer has spread to the lymph nodes near the breast.

Medical Treatments

• Chemotherapy: The backbone of treatment for triple-negative breast cancer, chemotherapy uses strong medicines to kill cancer cells often before (neoadjuvant) or after surgery (adjuvant).
• Targeted therapy: For patients with BRCA mutations, PARP inhibitors may be effective in selected patients.
• Immunotherapy: Drugs like checkpoint inhibitors can boost the immune system to fight triple-negative breast cancer.

Radiation Therapy

High-energy X-ray beams destroy remaining cancer cells after surgery, especially after a lumpectomy.

Proton Therapy: When Is It Applicable?

Available at Apollo Proton Cancer Centre, proton therapy uses protons instead of X-rays to deliver radiation more precisely to cancer cells. This allows doctors to target the tumor while minimizing damage to healthy surrounding tissue, including the heart and lungs. Proton therapy may be used for treating triple-negative breast cancer following surgery, in the following situations:

• When the tumor is located close to critical organs such as the heart or lungs, especially in left-sided breast cancers.
• In patients who require radiation of the internal mammary nodes.
• In patients with cardiac risk factors such as diabetes mellitus, hypertension, obesity and or an underlying cardiac ailment.
• In patients who have received anthracyclines and or trastuzumab and thus have a higher risk of cardiac side effects of treatment.
• In younger patients, to reduce long-term side effects from radiation exposure, especially the risk of second cancers.
• In patients suffering from bilateral breast cancer.
• For patients who have already received radiation to the chest and require additional treatment.
• In complex cases such as pectus excavatum where precision is essential to reduce radiation-related complications.

While proton therapy is not required for all patients with triple-negative breast cancer, it can be especially beneficial in selected cases where traditional radiation may pose higher risks.

What is the Prognosis for Triple-Negative Breast Cancer?

Triple-negative breast cancer has a less favorable prognosis compared to other breast cancers because it grows quickly and has fewer treatment options.

Survival rates vary by population and treatment advances. Approximate 5-year survival:

• Stage I: 90%
• Stage II: 65–75%
• Stage III: 40–50%
• Stage IV: 10-15%

Prognosis depends on tumor size, spread, response to treatment, and overall health. The good news is that triple-negative breast cancer often responds well to chemotherapy, especially if caught early.

Screening and Prevention of Triple-Negative Breast Cancer

People from around the world come to Apollo Hospitals for the treatment of triple-negative breast cancer. Our international patient services team will guide you all the way from seeking the first virtual connect all the way to treatment in India and then returning home post treatment.

Services include:

• Medical opinions and scheduling
• Pre-arrival medical review of reports and imaging.
• Travel and logistics
• Assistance with visa invitation letters, airport transfers, and nearby accommodation options.
• Dedicated international patient coordinators to guide through each step.
• Language and cultural support
• Interpreter services in multiple languages.
• Clear, simple explanations at every stage with written care plans.
• Financial coordination
• Transparent treatment estimates and packages when possible.
• Support with international payment methods and insurance coordination.
• Continuity of care
• Shared records, imaging, and treatment summaries for home doctors.
• Telemedicine follow-ups for convenience after returning home.

About Apollo Proton Cancer Centre

Apollo Proton Cancer Centre (APCC) is the first proton therapy centre in India. APCC has a fully integrated treatment suite that offers the most advanced treatment in surgical, radiation and medical oncology procedures. True to the Apollo Pillars of Expertise and Excellence, the Centre brings together a powerful team of clinicians renowned globally for cancer care.

At Apollo Proton Cancer Centre (APCC), we combine advanced technology with globally renowned clinical expertise to deliver superior outcomes and improved quality of life to our patients.